Trials / Completed
CompletedNCT00560950
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 59 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.
Detailed description
This study is an extension study (V110-007-10) which met requirements for posting on clinicaltrials.gov. The original study (V110-007-00) was completed in 2004 and did not meet the criteria for registration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | pneumococcal 23v polysaccharide vaccine | Duration of Treatment: Single vaccination on Day 1 |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2007-11-20
- Last updated
- 2017-04-11
- Results posted
- 2009-05-25
Source: ClinicalTrials.gov record NCT00560950. Inclusion in this directory is not an endorsement.